Publications

5674 Results

Long-Term Follow-up and updated analysis from S0221, Comparing Alternative Dose-Schedules of Adjuvant Anthracyclne/Taxane Therapy in High-Risk Early Breast Cancer

Authors
A Ali;W Barlow;HCF Moore;T Hobday;J Stewart;C Isaacs;M Salim;J Cho;K Rinn;K Albain;H Chew;G Burton;T Moore;G Srkalovic;B McGregor;L Flaherty;DL Lew;J Gralow;G Hortobagyi;P Sharma;L Pusztai;G Budd
Journal / Conference
San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), rapid fire presentation (oral)
Year
2024
Research Committee(s)
Breast
Study Number(s)
S0221

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Younger Patients with Mantle Cell Lymphoma: Clinical Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Authors
N Wagner-Johnston;O Jegede;S Spurgeon;K Maddocks;D Yang;J Romanoff;J Paludo;P Caimi;N Bartlett;P Reagan;Y Sawalha;M Hoffmann;B Hu;A Aziz;H Marques;L Kostakoglu Shields;J Leonard;JW Friedberg;B Kahl
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), oral
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/EA8141

Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer

Authors
B Felsheim;A Fernandez Martinez;C Fan;A Pfefferle;M Hayward;K Hoadley;G Somlo;L Carey;W Sikov;C Perou
Journal / Conference
San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), poster
Year
2024
Research Committee(s)
Breast
Study Number(s)
CTSU/C40603

Association of Baseline Global Inflammation Score with Clinical Outcomes: Secondary Analysis from Alliance A011502

Authors
S Gandhi;K Ballman;S Reed;M Holmes;K Visvanathan;B Symington;M Carvan;C Matyka;A Weiss;E Winer;W Razaq;L Carey;A Partridge;W Chen
Journal / Conference
San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), poster
Year
2024
Research Committee(s)
Breast
Study Number(s)
CTSU/A011502

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Authors
J Amengual;P Reagan;H Li;T Al Baghdadi;H Saeed;R Vaidya;J Unger;A Danilov;M LeBlanc;JW Friedberg;S Smith
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Lymphoma
Study Number(s)
S2207

Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Authors
V Liu;M Othus;R Ries;J Neru;E Pogosova-Agadjanyan;F Appelbaum;L Beppu;T Chauncey;H Erba;J Godwin;M Fitzgibbon;M Fang;A Moseley;J Radich;C Willman;F Wu;S Meshinchi;D Stirewalt
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Leukemia

Representation of Minorities in Therapeutic Clinical Trials – A 15-Year Review of Lymphoma Cooperative Group Studies

Authors
A Alencar;E Paskett;S Geyer;L Pederson;T Dokter;N Ghosh;K Adekola;J Unger;O Jegede;J Friedberg;B Kahl;S Dinner;N Bartlett;K Blum;J Leonard
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), oral
Year
2024
Research Committee(s)
Cancer Care Delivery and Lymphoma

Consent to Future Use of Residual and Banked Specimens among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024

Authors
D Olivieri;A Berridge-Green;M Othus;J Radich;A Advani;H Erba;R Walter
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Leukemia

The Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Adult Patients with B-cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Trial

Authors
D DeAngelo;V Yin;A Advani;S Lugar;J Fulcher;M Liedtke;G Uy;S Dinner;L Wilde;H Erba;M Litzow;R Stone;P Mohindra;J Bogart;W Stock
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), oral
Year
2024
Research Committee(s)
Leukemia

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Authors
J Altman;Sun;Perl;Little;Gore;L Michaelis;G Uy;Y Abaza;Abedin;Reagan;Atallah;Luger;M Litzow
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Leukemia
Study Number(s)
MYELOMATCH